Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Change in Accured Expenses data on file, last reported at $738682.0 in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses fell 34.92% year-over-year to $738682.0; the trailing twelve-month figure through Dec 2025 stood at $388218.0 (down 23.4% YoY), and the FY2025 full-year result was $388218.0, down 23.4% from the prior year.
• Change in Accured Expenses grew to $738682.0 in Q4 2025, from $355101.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.2 million in Q4 2022 to a low of -$770968.0 in Q1 2025.
• A 5-year average of $75986.3 and a median of -$2379.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 10489.49% in 2023 and jumped 1137.63% in 2025, its largest moves.
• Tracing MNPR's Change in Accured Expenses over 5 years: stood at $403967.0 in 2021, then soared by 196.03% to $1.2 million in 2022, then plunged by 117.81% to -$212999.0 in 2023, then jumped by 632.91% to $1.1 million in 2024, then slumped by 34.92% to $738682.0 in 2025.
• Business Quant data shows MNPR's Change in Accured Expenses at $738682.0 in Q4 2025, $355101.0 in Q3 2025, and $65403.0 in Q2 2025.